429 related articles for article (PubMed ID: 33166791)
1. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
Mankor JM; Disselhorst MJ; Poncin M; Baas P; Aerts JGJV; Vroman H
EBioMedicine; 2020 Dec; 62():103040. PubMed ID: 33166791
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
4. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
[TBL] [Abstract][Full Text] [Related]
5. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.
Desai AP; Kosari F; Disselhorst M; Yin J; Agahi A; Peikert T; Udell J; Johnson SH; Smadbeck J; Murphy S; Karagouga G; McCune A; Schaefer-Klein J; Borad MJ; Cheville J; Vasmatzis G; Baas P; Mansfield A
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37279993
[TBL] [Abstract][Full Text] [Related]
6. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
Tada A; Minami T; Kitai H; Higashiguchi Y; Tokuda M; Higashiyama T; Negi Y; Horio D; Nakajima Y; Otsuki T; Mikami K; Takahashi R; Nakamura A; Kitajima K; Ohmuraya M; Kuribayashi K; Kijima T
Lung Cancer; 2023 Jun; 180():107219. PubMed ID: 37146474
[TBL] [Abstract][Full Text] [Related]
8. Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment.
Disselhorst MJ; de Vries R; Quispel-Janssen J; Wolf-Lansdorf M; Sterk PJ; Baas P
Eur J Cancer; 2021 Jul; 152():60-67. PubMed ID: 34087572
[TBL] [Abstract][Full Text] [Related]
9. Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.
Greiner J; Götz M; Hofmann S; Schrezenmeier H; Wiesneth M; Bullinger L; Döhner H; Schneider V
Cancer Immunol Immunother; 2020 Apr; 69(4):629-640. PubMed ID: 32020256
[TBL] [Abstract][Full Text] [Related]
10. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus ipilimumab in malignant pleural mesothelioma.
Travert C; Tomasini P; Greillier L
Expert Rev Anticancer Ther; 2022 Aug; 22(8):815-822. PubMed ID: 35835722
[TBL] [Abstract][Full Text] [Related]
12. FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma.
Wright K
Oncology (Williston Park); 2020 Nov; 34(11):502-503. PubMed ID: 33206991
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
14. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
15. Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
Hu ZI; Ghafoor A; Sengupta M; Hassan R
Cancer; 2021 Apr; 127(7):1010-1020. PubMed ID: 33620732
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
Nakajima EC; Vellanki PJ; Larkins E; Chatterjee S; Mishra-Kalyani PS; Bi Y; Qosa H; Liu J; Zhao H; Biable M; Hotaki LT; Shen YL; Pazdur R; Beaver JA; Singh H; Donoghue M
Clin Cancer Res; 2022 Feb; 28(3):446-451. PubMed ID: 34462287
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
Carreau NA; Pavlick AC
Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab plus ipilimumab in advanced melanoma.
Wolchok JD; Kluger H; Callahan MK; Postow MA; Rizvi NA; Lesokhin AM; Segal NH; Ariyan CE; Gordon RA; Reed K; Burke MM; Caldwell A; Kronenberg SA; Agunwamba BU; Zhang X; Lowy I; Inzunza HD; Feely W; Horak CE; Hong Q; Korman AJ; Wigginton JM; Gupta A; Sznol M
N Engl J Med; 2013 Jul; 369(2):122-33. PubMed ID: 23724867
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
[TBL] [Abstract][Full Text] [Related]
20. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
